You are here: Industry Insights > Novartis

News List

USFDA awards Breakthrough Therapy designation to Novartis’ asciminib pharmaceutical-business-review
February 10, 2021
Novartis has announced that the novel investigational treatment asciminib, specifically targeting the ABL myristoyl pocket (STAMP), has been awarded Breakthrough Therapy designation (BTD) by the US Food and Drug Administration (FDA).
AI to be most transformative technology for pharma, finds survey europeanpharmaceuticalreview
February 01, 2021
A new report suggests artificial intelligence (AI) will be the most disruptive technology in the pharmaceutical industry this year and beyond.
Novartis Inks Contract Manufacturing Deal for Pfizer-BioNTech COVID-19 Vaccine contractpharma
February 01, 2021
Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine.
Novartis in discussions to help produce COVID-19 vaccines, tests expresspharma
January 29, 2021
Novartis last year agreed to license two of Molecular Partners’ antiviral drugs that it hopes to use to treat COVID-19 patients.
Novartis Invests in Credence MedSystems contractpharma
January 28, 2021
Drug delivery company Credence MedSystems announced that Novartis has made a strategic investment in the company.
Pharma companies move towards systematic access planning approaches: 2021 Access to Medicine Index expresspharma
January 27, 2021
A new shift in pharma company policy could shorten the time people in lower-income countries must typically wait for new medicines and vaccines, reports the 2021 Access to Medicine Index.
Novartis, GSK team up for $3.6m genetic diversity research in Africa pharmaceutical-business-review
January 22, 2021
Swiss pharma giant Novartis and British pharmaceuticals company GSK have teamed up to conduct scientific research linking genetic diversity in Africa and its potential impact on response to drug therapeutics.
Novartis Expands Oncology Pipeline with In-Licensing of Tislelizumab from BeiGene americanpharmaceuticalreview
January 20, 2021
Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene in major markets outside of China. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages.
Novartis Announces FDA Approval of Xolair for Nasal Polyps americanpharmaceuticalreview
December 22, 2020
Novartis announced the US Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age ...
US FDA declines approval for Novartis’ inclisiran expresspharma
December 21, 2020
The drug regulator cited unresolved facility inspection issues for denying approval.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page